A Phase III Randomized, Open-Label, Multicenter Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray Formulations in Elderly Patients (≥75 Years Old) With Nocturia

Trial Profile

A Phase III Randomized, Open-Label, Multicenter Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray Formulations in Elderly Patients (≥75 Years Old) With Nocturia

Completed
Phase of Trial: Phase III

Latest Information Update: 30 May 2014

At a glance

  • Drugs Desmopressin (Primary)
  • Indications Nocturia
  • Focus Adverse reactions; Registrational
  • Sponsors Serenity Pharmaceuticals Corporation
  • Most Recent Events

    • 17 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top